Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

Efficacy:
Sinaptica's neuromodulation therapy, SinaptiStim, has shown a 44% reduction in Alzheimer's disease progression over 12 months in a Phase II clinical trial.

Mechanism:
The therapy uses personalized, non-invasive brain stimulation targeting the Default Mode Network (DMN) via the precuneus, enhancing neuroplasticity and preserving memory connections.

Clinical Outcomes:
Patients treated with SinaptiStim demonstrated significant improvements in cognitive and functional endpoints, including stability in daily living activities and reduced behavioral disturbances.

Future Plans:
Following these positive results, Sinaptica plans to advance to a Phase III trial, expected to commence in 2025, to further validate the therapy's effectiveness.

Market Potential:
The global neuromodulation device market is projected to reach $11.4 billion by 2033, indicating a growing interest in innovative treatments like Sinaptica's therapy.